Clinical Trial Update: Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas [EARLY_Phase 1]

View source ↗

Summary

An early-phase pilot study at Johns Hopkins evaluated a combination of CY (cyclophosphamide), pembrolizumab, GVAX pancreatic cancer vaccine, and IMC-CS4 (LY3022…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• GVAX pancreatic cancer vaccine (GVAX pancreatic cancer vaccine)
• IMC-CS4
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Cancer | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2024-10-15